Research review priorities
Supplement research priorities
These are research priorities, not recommendations. We selected decisions where public interest, plausible benefit, evidence maturity, and safety stakes make a careful synthesis especially useful.
- priority dossiers
- 148
- claim-level questions
- 444
- study extraction underway
- 148
01 / PRIORITY
How priorities were selected
Priority reflects relevance to healthy aging, frequency of real-world use, maturity of human evidence, the cost of a wrong decision, and the need to separate a valid narrow use from broader marketing claims. It does not rank efficacy or imply that everyone should take the product.
02 / EXTRACTION
What happens next
For every question, we screen the PubMed candidate set, connect multiple publications from the same trial, extract population, dose, comparator, duration, outcomes, harms, and funding, then synthesize supportive, mixed, negative, and safety findings together.
Only screened studies enter audited study and participant totals. Search-result counts and the papers listed here as questions never become evidence by themselves.Hibiscus sabdariffa
- Review stage
- Extracting studies
- audited research papers
- 1
Why this is a research priority
Hibiscus modestly lowers short-term blood pressure versus placebo but not active treatment, with uncertain long-term outcomes and formulation.
Questions being reviewed
- Which tea or extract dose meaningfully lowers ambulatory or clinic blood pressure and in whom?
- How does hibiscus compare with medication and does it affect cardiovascular events rather than surrogate markers?
- What hypotension, antihypertensive, diabetes-drug, diuretic, liver, pregnancy, and product-quality limits apply?
Cocoa flavanols
- Review stage
- Extracting studies
- audited research papers
- 1
Why this is a research priority
A large outcomes trial missed its primary cardiovascular endpoint, while a secondary mortality signal needs confirmation and should not be generalized to chocolate.
Questions being reviewed
- Do standardized cocoa flavanols reduce prespecified cardiovascular events or mortality?
- Are cognitive, blood-pressure, and endothelial findings clinically meaningful and independently replicated?
- What dose, epicatechin content, calories, stimulant, heavy-metal, medicine, and pregnancy limits apply?
Grape seed extract
- Review stage
- Extracting studies
- audited research papers
- 1
Why this is a research priority
Small lipid changes come from short trials and surrogate outcomes, without demonstrated cardiovascular-event benefit.
Questions being reviewed
- Does standardized grape seed extract produce durable, clinically meaningful lipid changes?
- Do blood-pressure or endothelial changes translate into fewer cardiovascular events?
- What bleeding, anticoagulant, surgery, allergy, pregnancy, and product-standardization limits apply?
Pine bark extract
- Review stage
- Extracting studies
- audited research papers
- 1
Why this is a research priority
Cochrane found evidence too small, heterogeneous, and biased to support efficacy or safety for any chronic disorder.
Questions being reviewed
- Which chronic condition, if any, has adequately powered and independently replicated benefit?
- Do results for proprietary Pycnogenol apply to other pine bark extracts?
- What bleeding, immune, glucose, blood-pressure, medicine, surgery, and pregnancy limits apply?
Quercetin
- Review stage
- Extracting studies
- audited research papers
- 1
Why this is a research priority
Modest pooled blood-pressure changes remain clinically uncertain, dose subgroup comparisons are indirect, and event outcomes are absent.
Questions being reviewed
- Does quercetin meaningfully lower ambulatory or clinic blood pressure as add-on care?
- Are dose-response and formulation differences supported by direct comparisons?
- What kidney, bleeding, CYP/transport, antibiotic, oncology, pregnancy, and high-dose limits apply?
03 / SOURCES
Research standards
The review begins with federal evidence summaries and PubMed records, then moves to trial-level extraction. Product claims or another publisher’s evidence grade are not copied into the ledger.